Teladoc Health (NYSE:TDOC) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Teladoc Health (NYSE:TDOC) had its price target lifted by equities researchers at Deutsche Bank Aktiengesellschaft from $10.00 to $12.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “hold” rating on the health services provider’s stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential upside of 30.58% from the company’s previous close.

A number of other brokerages have also recently issued reports on TDOC. Royal Bank of Canada upped their target price on Teladoc Health from $9.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. TD Cowen reduced their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Thursday. Canaccord Genuity Group dropped their target price on shares of Teladoc Health from $25.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Stifel Nicolaus cut their target price on Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, August 1st. Finally, Evercore ISI boosted their price target on Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Fourteen research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $11.97.

Teladoc Health Price Performance

NYSE:TDOC traded up $0.19 during trading hours on Friday, reaching $9.19. 4,740,791 shares of the company were exchanged, compared to its average volume of 5,466,777. The business has a 50 day moving average of $8.41 and a 200 day moving average of $9.72. Teladoc Health has a 1-year low of $6.76 and a 1-year high of $22.54. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The company has a market capitalization of $1.57 billion, a P/E ratio of -1.56 and a beta of 0.91.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 9.40% and a negative net margin of 37.91%. The business had revenue of $640.51 million during the quarter, compared to the consensus estimate of $630.50 million. Research analysts forecast that Teladoc Health will post -1.18 EPS for the current year.

Insider Transactions at Teladoc Health

In other news, Director Thomas Mckinley purchased 4,000 shares of Teladoc Health stock in a transaction dated Thursday, September 12th. The stock was purchased at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the transaction, the director now directly owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Thomas Mckinley bought 4,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $7.69 per share, with a total value of $30,760.00. Following the completion of the purchase, the director now directly owns 39,077 shares of the company’s stock, valued at $300,502.13. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Michael Willem Waters sold 4,218 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $30,200.88. Following the completion of the transaction, the chief operating officer now directly owns 78,309 shares of the company’s stock, valued at approximately $560,692.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,588 shares of company stock valued at $268,831 over the last three months. Company insiders own 0.95% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently modified their holdings of the company. Point72 Asset Management L.P. grew its position in Teladoc Health by 221.9% during the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock valued at $51,865,000 after acquiring an additional 3,655,436 shares during the last quarter. Rubric Capital Management LP purchased a new position in Teladoc Health in the 2nd quarter worth $45,267,000. Clearline Capital LP grew its stake in shares of Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after buying an additional 3,483,665 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Teladoc Health in the third quarter worth about $15,801,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Teladoc Health by 1.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 916,129 shares of the health services provider’s stock valued at $8,960,000 after acquiring an additional 14,910 shares during the last quarter. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.